Treatment of Generalized Anxiety Disorder in Children

First-Line Treatment Approach

The American Academy of Child and Adolescent Psychiatry recommends cognitive-behavioral therapy (CBT) as the initial treatment for a 12-year-old with Generalized Anxiety Disorder (GAD), as it has demonstrated efficacy and avoids medication-related risks 1, 2
For moderate to severe GAD with significant functional impairment or inadequate response to CBT alone, consider adding pharmacotherapy, with the American Academy of Child and Adolescent Psychiatry suggesting this approach 1
Combination treatment (CBT plus medication) may be more effective than either treatment alone for anxiety disorders in children and adolescents, according to the American Academy of Child and Adolescent Psychiatry 1

The American Academy of Child and Adolescent Psychiatry recommends fluoxetine as the first-line medication for children with anxiety disorders, including GAD, due to its efficacy and safety profile 3, 4
Multiple practice guidelines, including those from the American Academy of Child and Adolescent Psychiatry, consistently recommend fluoxetine as the preferred first-line medication option for pediatric anxiety 3, 4
The American Academy of Child and Adolescent Psychiatry suggests that SNRIs, such as duloxetine, could be considered for children 6-18 years with GAD if SSRIs are ineffective or not tolerated 1, 5
Duloxetine is the only SNRI with FDA indication for GAD in children (age 7 and older), as noted by the American Academy of Child and Adolescent Psychiatry 5

Close monitoring for adverse effects is essential, particularly during the first 4 weeks of treatment, with the American Academy of Child and Adolescent Psychiatry emphasizing the importance of this monitoring 3, 2
Key adverse effects to monitor include suicidal ideation and behavior, behavioral activation/agitation, gastrointestinal symptoms, weight changes, and sleep disturbances, according to the American Academy of Child and Adolescent Psychiatry 1, 2, 5
The American Academy of Child and Adolescent Psychiatry recommends using standardized symptom rating scales to systematically track treatment response 1
Parental oversight of medication administration and monitoring for side effects is crucial, as emphasized by the American Academy of Child and Adolescent Psychiatry 1

The American Academy of Child and Adolescent Psychiatry recommends avoiding tricyclic antidepressants (TCAs) due to unfavorable risk-benefit profile in children 3, 4
Paroxetine is not recommended for pediatric anxiety disorders, according to the American Academy of Child and Adolescent Psychiatry 3, 4
Benzodiazepines should be avoided as primary treatment due to risk of dependence and potential for disinhibition in children, as noted by the American Academy of Child and Adolescent Psychiatry 2

Failing to provide adequate psychoeducation to both the child and parents about expected benefits and potential risks of medication is a pitfall to avoid, according to the American Academy of Child and Adolescent Psychiatry 1, 2
Inadequate monitoring, particularly during the initial weeks of treatment, is another pitfall to avoid, as emphasized by the American Academy of Child and Adolescent Psychiatry 3, 2